Literature DB >> 9838256

Etiology and pathogenetic mechanisms of optic disc swelling with visual loss. An interdisciplinary prospective pilot study of 102 cases.

J Stammen1, R Unsöld, G Arendt, E G Vester, P Heering, H Freund, B Strauer, B Grabensee.   

Abstract

A nonrandomized, prospective, interdisciplinary pilot study of 102 patients with noncompressive optic disc swelling with visual loss (ODSWVL) was performed in order to investigate etiologic and pathogenetic mechanisms. Forty-six patients suffered from underlying inflammatory disease. Seventeen patients suffered from highly probable cardiogenic embolization, 16 patients from multiple vascular risk factors. The remaining patients of the noninflammatory disease group suffered from leukemia, previously unknown or severely decompensated diabetes mellitus, acute arterial hypertension, different kinds of coagulopathies and others. Ninety-six of the 102 patients required medical treatment according to general medical standards. Inhomogeneity of the underlying disease processes explains the ineffectiveness of different monotherapies in previous studies. Interdisciplinary search for the underlying causes allows causative treatment. ODSWVL and anterior ischemic optic neuropathy in particular seem to be a common final pathway of various pathogenetic mechanisms due to different etiologies rather than a disease entity by itself.

Entities:  

Mesh:

Year:  1999        PMID: 9838256     DOI: 10.1159/000027392

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

Review 1.  [Anterior ischemic optic neuropathy: Etiology, pathogenetic mechanisms and therapy].

Authors:  R Unsöld
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

Review 2.  Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature.

Authors:  L Delval; J Klastersky
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.